Log in

Karyopharm Therapeutics Stock Forecast, Price & News

+0.23 (+1.43 %)
(As of 09/18/2020 12:00 AM ET)
Today's Range
Now: $16.32
50-Day Range
MA: $15.10
52-Week Range
Now: $16.32
Volume1.50 million shs
Average Volume1.67 million shs
Market Capitalization$1.20 billion
P/E RatioN/A
Dividend YieldN/A
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's lead compound, XPOVIOTM (selinexor), received accelerated approval from the FDA in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency (EMA). In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.
Read More
Karyopharm Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.81 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:KPTI



Sales & Book Value

Annual Sales$40.89 million
Book Value$0.79 per share


Net Income$-199,590,000.00
Net Margins-228.44%


Market Cap$1.20 billion
Next Earnings Date11/2/2020 (Estimated)
+0.23 (+1.43 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KPTI News and Ratings via Email

Sign-up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Karyopharm Therapeutics (NASDAQ:KPTI) Frequently Asked Questions

How has Karyopharm Therapeutics' stock been impacted by COVID-19?

Karyopharm Therapeutics' stock was trading at $21.24 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, KPTI stock has decreased by 23.2% and is now trading at $16.32.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Karyopharm Therapeutics?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Karyopharm Therapeutics

When is Karyopharm Therapeutics' next earnings date?

Karyopharm Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Karyopharm Therapeutics

How were Karyopharm Therapeutics' earnings last quarter?

Karyopharm Therapeutics Inc (NASDAQ:KPTI) issued its earnings results on Tuesday, August, 4th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.57) by $0.06. The company had revenue of $33.51 million for the quarter, compared to analysts' expectations of $28.03 million. Karyopharm Therapeutics had a negative net margin of 228.44% and a negative return on equity of 186.76%.
View Karyopharm Therapeutics' earnings history

What price target have analysts set for KPTI?

10 analysts have issued 12-month price objectives for Karyopharm Therapeutics' shares. Their forecasts range from $26.00 to $41.00. On average, they expect Karyopharm Therapeutics' stock price to reach $33.22 in the next year. This suggests a possible upside of 103.6% from the stock's current price.
View analysts' price targets for Karyopharm Therapeutics

Who are some of Karyopharm Therapeutics' key competitors?

What other stocks do shareholders of Karyopharm Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Crispr Therapeutics (CRSP), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), Micron Technology (MU), AbbVie (ABBV), Bristol-Myers Squibb (BMY), InVitae (NVTA) and Sorrento Therapeutics (SRNE).

Who are Karyopharm Therapeutics' key executives?

Karyopharm Therapeutics' management team includes the following people:
  • Dr. Michael G. Kauffman, Co-Founder, CEO & Director (Age 56)
  • Dr. Sharon Shacham, Co-Founder, Pres, Chief Scientific Officer & Co-Chairman of Scientific Advisory Board (Age 49)
  • Mr. Christopher Brett Primiano, Exec. VP, Chief Bus. Officer, Gen. Counsel & Sec. (Age 38)
  • Dr. Mansoor Raza Mirza, Clinical Consultant, Member of Scientific Advisory Board & Director (Age 58)
  • Mr. Michael P. Mason, Sr. VP, CFO & Treasurer (Age 44)

What is Karyopharm Therapeutics' stock symbol?

Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."

Who are Karyopharm Therapeutics' major shareholders?

Karyopharm Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.85%), Frontier Capital Management Co. LLC (3.82%), Goldman Sachs Group Inc. (2.72%), Emerald Advisers LLC (1.70%), Emerald Mutual Fund Advisers Trust (1.42%) and Two Sigma Advisers LP (1.23%). Company insiders that own Karyopharm Therapeutics stock include Christopher Brett Primiano, Jatin Shah, John Demaree, Ltd Chione, Mansoor Raza Mirza, Michael Kauffman, Ran Frenkel and Sharon Shacham.
View institutional ownership trends for Karyopharm Therapeutics

Which institutional investors are selling Karyopharm Therapeutics stock?

KPTI stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Atom Investors LP, Caption Management LLC, Sei Investments Co., Bank of New York Mellon Corp, Virtus ETF Advisers LLC, and Arizona State Retirement System. Company insiders that have sold Karyopharm Therapeutics company stock in the last year include Christopher Brett Primiano, Jatin Shah, Mansoor Raza Mirza, Michael Kauffman, Ran Frenkel, and Sharon Shacham.
View insider buying and selling activity for Karyopharm Therapeutics

Which institutional investors are buying Karyopharm Therapeutics stock?

KPTI stock was purchased by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Frontier Capital Management Co. LLC, Vanguard Group Inc., Balyasny Asset Management LLC, Emerald Advisers LLC, Two Sigma Advisers LP, Emerald Mutual Fund Advisers Trust, and Nuveen Asset Management LLC.
View insider buying and selling activity for Karyopharm Therapeutics

How do I buy shares of Karyopharm Therapeutics?

Shares of KPTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Karyopharm Therapeutics' stock price today?

One share of KPTI stock can currently be purchased for approximately $16.32.

How big of a company is Karyopharm Therapeutics?

Karyopharm Therapeutics has a market capitalization of $1.20 billion and generates $40.89 million in revenue each year. The company earns $-199,590,000.00 in net income (profit) each year or ($3.22) on an earnings per share basis. Karyopharm Therapeutics employs 332 workers across the globe.

What is Karyopharm Therapeutics' official website?

The official website for Karyopharm Therapeutics is www.karyopharm.com.

How can I contact Karyopharm Therapeutics?

Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The company can be reached via phone at 617-658-0600 or via email at [email protected]

This page was last updated on 9/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.